Literature DB >> 10821605

Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network.

C A Holland1, Y Ma, B Moscicki, S J Durako, L Levin, C M Wilson.   

Abstract

BACKGROUND AND OBJECTIVES: In adolescents and young adults, multiple studies have identified sexual activity and behaviors as significant risk factors for acquiring both human cytomegalovirus (HCMV) and hepatitis B virus (HBV). However, there are no reports on the prevalence or risk factors for infection of these viruses and hepatitis C virus (HCV) in an adolescent population with sexually acquired HIV. GOALS: To examine the seroprevalence and risk factors of HBV, HCV, and HCMV infection in a population of HIV-infected male and female adolescents and in an age- and risk behavior-matched HIV-uninfected cohort. STUDY
DESIGN: A cross-sectional analysis of HBV, HCV, and HCMV infections in a cohort of HIV-infected and HIV-uninfected adolescents.
RESULTS: Adolescent males infected with HIV were more likely to have evidence of HBV and HCMV infection than HIV-uninfected males (23.7% versus 0%, respectively, for HBV, P = 0.008; 79.7% versus 50%, respectively, for HCMV, P = 0.004). HIV-infected females were more likely to have evidence of HCMV infection (78.5% versus 61.4%, P = 0.003) than HIV-uninfected females. No significant difference was found for HBV infection in the two groups of females. The rate of HCV infection (1.6%) was too small to make comparisons between the groups. To determine whether the differences in infection rates for HBV and HCMV could be explained by factors other than HIV status, a variety of possible risk factors were examined using univariate and multivariate analyses. A significant risk factor for HBV and HCMV infections for males was a homosexual or bisexual orientation. For females, a risk factor for HBV infection was having more than 10 lifetime sexual partners; for HCMV infection, HIV infection was the only risk factor. In addition, in the HIV-infected cohort, 15% of females and 36% of males who were seropositive for HBV had evidence of active HBV infection.
CONCLUSIONS: These results emphasize the need for continued development of primary and secondary prevention programs and clinical screening and treatment for HBV and HCMV in adolescents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821605     DOI: 10.1097/00007435-200005000-00012

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  Identification of three immunologic correlates for HIV type 1 pathogenesis in youth.

Authors:  Wei Song; Yufeng Li; Craig M Wilson; Jianming Tang
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-13       Impact factor: 2.205

Review 2.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

3.  Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness.

Authors:  Marian I Butterfield; Hayden B Bosworth; Karen M Stechuchak; Richard Frothingham; Lori A Bastian; Keith G Meador; Marvin Swartz; Ron D Horner
Journal:  J Natl Med Assoc       Date:  2004-01       Impact factor: 1.798

4.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

5.  The convergent epidemiology of tuberculosis and human cytomegalovirus infection.

Authors:  Frank Cobelens; Nico Nagelkerke; Helen Fletcher
Journal:  F1000Res       Date:  2018-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.